Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Pipeline Pivot | Viracta narrows focus to Nana-val for EBV+ lymphomas, pausing solid tumor program to streamline development and regulatory pathways |
Regulatory Clarity | FDA discussions yield potential accelerated approval filing for Nana-val in 2026, offering a clearer path to market for Viracta's lead candidate |
Financial Challenges | With $30M cash reserves and a reduced workforce, Viracta faces financial hurdles while aiming to extend runway for key clinical milestones |
Market Positioning | Explore Viracta's strategy to dominate the EBV+ lymphoma niche, balancing specialized focus against broader market opportunities |
Metrics to compare | VIRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVIRXPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −3.2x | −0.6x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | −0.1x | 0.5x | 2.6x | |
Price / LTM Sales | - | 12.3x | 3.1x | |
Upside (Analyst Target) | - | 261.9% | 47.1% | |
Fair Value Upside | Unlock | 17.2% | 8.1% | Unlock |